The Journal of
Clinical Psychiatry
The Official Journal of the American Society of Clinical Psychopharmacology
Peer-Reviewed, Evidence-Based Scientific Information
Adjunctive Oral Ziprasidone in Patients With Acute Mania Treated With Lithium or Divalproex, Part 2: Influence of Protocol-Specific Eligibility Criteria on Signal Detection
Gary S. Sachs, Douglas G. Vanderburg, Suzanne Edman, Onur N. Karayal, Sheela Kolluri, Mary Bachinsky, and Idil Cavus
Ziprasidone is currently FDA-approved as monotherapy for the treatment of patients with bipolar manic or mixed episodes. In a 3-week, randomized, placebo-controlled study, Gary Sachs and colleagues evaluated patients who received placebo with a mood stabilizer (lithium or divalproex) or adjunctive ziprasidone at a low or high dose with a mood stabilizer. Efficacy was measured as a change in the Young Mania Rating Scale score from baseline to week 3.
[Full Text] [Audio Summary]

For more articles, visit the Journal at

To receive E-Lerts from both The Journal of Clinical Psychiatry and The Primary Care Companion, update your profile.

Like us on Facebook
Follow us on Twitter
You are receiving this update as a benefit of your membership.
To ensure delivery of these messages, add to your address book. If you would not like to receive further E-Lerts, go to and click the "Unsubscribe from E-Lerts" link. If you are having trouble unsubscribing, contact the web administrator for assistance.
If you are having trouble with your membership, contact our circulation department. Direct any other questions or comments to the web administrator.
Please do not reply directly to this e-mail.
If you cannot read this, go to
Physicians Postgraduate Press, Inc. | 850 Ridge Lake Boulevard, Suite 300 | Memphis, TN 38120
© Copyright 2012, Physicians Postgraduate Press, Inc. All rights reserved.